nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—Estradiol—osteoporosis	0.343	1	CrCtD
Fulvestrant—ESR2—osteoporosis	0.105	0.619	CbGaD
Fulvestrant—Estradiol—Estropipate—osteoporosis	0.0744	0.418	CrCrCtD
Fulvestrant—ESR1—osteoporosis	0.065	0.381	CbGaD
Fulvestrant—Estradiol—Conjugated Estrogens—osteoporosis	0.0564	0.317	CrCrCtD
Fulvestrant—ESRRA—Estradiol—osteoporosis	0.0481	0.207	CbGbCtD
Fulvestrant—Estradiol—Ethinyl Estradiol—osteoporosis	0.0474	0.266	CrCrCtD
Fulvestrant—ESR2—Estropipate—osteoporosis	0.0358	0.155	CbGbCtD
Fulvestrant—ESR2—Raloxifene—osteoporosis	0.0239	0.103	CbGbCtD
Fulvestrant—ESR2—Ethinyl Estradiol—osteoporosis	0.0231	0.0996	CbGbCtD
Fulvestrant—ESR1—Estropipate—osteoporosis	0.0184	0.0792	CbGbCtD
Fulvestrant—ESR2—Conjugated Estrogens—osteoporosis	0.0169	0.0731	CbGbCtD
Fulvestrant—ESR2—Estradiol—osteoporosis	0.0149	0.0642	CbGbCtD
Fulvestrant—ESR1—Raloxifene—osteoporosis	0.0122	0.0528	CbGbCtD
Fulvestrant—ESR1—Ethinyl Estradiol—osteoporosis	0.0118	0.051	CbGbCtD
Fulvestrant—ESR1—Conjugated Estrogens—osteoporosis	0.00868	0.0374	CbGbCtD
Fulvestrant—ESR1—Estradiol—osteoporosis	0.00762	0.0329	CbGbCtD
Fulvestrant—NR1H4—skull—osteoporosis	0.00336	0.528	CbGeAlD
Fulvestrant—CYP3A4—Estropipate—osteoporosis	0.00189	0.00813	CbGbCtD
Fulvestrant—CYP3A4—Calcitriol—osteoporosis	0.00189	0.00813	CbGbCtD
Fulvestrant—CYP3A4—Ergocalciferol—osteoporosis	0.00151	0.0065	CbGbCtD
Fulvestrant—ESR1—periosteum—osteoporosis	0.00129	0.202	CbGeAlD
Fulvestrant—CYP3A4—Raloxifene—osteoporosis	0.00126	0.00542	CbGbCtD
Fulvestrant—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00121	0.00524	CbGbCtD
Fulvestrant—CYP3A4—Cholecalciferol—osteoporosis	0.000971	0.00419	CbGbCtD
Fulvestrant—CYP3A4—Conjugated Estrogens—osteoporosis	0.000892	0.00385	CbGbCtD
Fulvestrant—CYP3A4—Estradiol—osteoporosis	0.000783	0.00338	CbGbCtD
Fulvestrant—EPHX2—uterus—osteoporosis	0.000488	0.0769	CbGeAlD
Fulvestrant—ESRRA—uterus—osteoporosis	0.000428	0.0673	CbGeAlD
Fulvestrant—ESRRA—bone marrow—osteoporosis	0.000363	0.0571	CbGeAlD
Fulvestrant—Estradiol—ESR2—osteoporosis	0.000292	0.396	CrCbGaD
Fulvestrant—Estradiol—SHBG—osteoporosis	0.000266	0.361	CrCbGaD
Fulvestrant—ESR2—uterus—osteoporosis	0.000257	0.0404	CbGeAlD
Fulvestrant—Estradiol—ESR1—osteoporosis	0.00018	0.244	CrCbGaD
Fulvestrant—ESR1—uterus—osteoporosis	0.000176	0.0277	CbGeAlD
Fulvestrant—NR1H4—Biological oxidations—CYP19A1—osteoporosis	6.48e-05	0.0031	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—FDPS—osteoporosis	6.29e-05	0.003	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PKM—osteoporosis	6.29e-05	0.003	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	6.08e-05	0.0029	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GPD2—osteoporosis	5.96e-05	0.00285	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PGLS—osteoporosis	5.96e-05	0.00285	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.93e-05	0.00283	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—U2AF1—osteoporosis	5.61e-05	0.00268	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.51e-05	0.00263	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PNP—osteoporosis	5.45e-05	0.0026	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ATIC—osteoporosis	5.45e-05	0.0026	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—IGF1—osteoporosis	5.18e-05	0.00247	CbGpPWpGaD
Fulvestrant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	5.16e-05	0.00247	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ANXA2—osteoporosis	5.15e-05	0.00246	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Risedronate—osteoporosis	5.15e-05	0.00107	CcSEcCtD
Fulvestrant—Angioedema—Zoledronate—osteoporosis	5.1e-05	0.00106	CcSEcCtD
Fulvestrant—Skin disorder—Risedronate—osteoporosis	5.1e-05	0.00106	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Calcitriol—osteoporosis	5.1e-05	0.00106	CcSEcCtD
Fulvestrant—Body temperature increased—Raloxifene—osteoporosis	5.09e-05	0.00105	CcSEcCtD
Fulvestrant—Abdominal pain—Raloxifene—osteoporosis	5.09e-05	0.00105	CcSEcCtD
Fulvestrant—Urticaria—Ibandronate—osteoporosis	5.06e-05	0.00105	CcSEcCtD
Fulvestrant—Body temperature increased—Ibandronate—osteoporosis	5.03e-05	0.00104	CcSEcCtD
Fulvestrant—Abdominal pain—Ibandronate—osteoporosis	5.03e-05	0.00104	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—PKM—osteoporosis	5.03e-05	0.0024	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—FDPS—osteoporosis	5.03e-05	0.0024	CbGpPWpGaD
Fulvestrant—Vertigo—Zoledronate—osteoporosis	5.02e-05	0.00104	CcSEcCtD
Fulvestrant—Leukopenia—Zoledronate—osteoporosis	5e-05	0.00104	CcSEcCtD
Fulvestrant—Haemoglobin—Estradiol—osteoporosis	4.97e-05	0.00103	CcSEcCtD
Fulvestrant—Infection—Pamidronate—osteoporosis	4.96e-05	0.00103	CcSEcCtD
Fulvestrant—Urticaria—Calcitriol—osteoporosis	4.95e-05	0.00103	CcSEcCtD
Fulvestrant—Haemorrhage—Estradiol—osteoporosis	4.94e-05	0.00103	CcSEcCtD
Fulvestrant—Hepatitis—Estradiol—osteoporosis	4.94e-05	0.00103	CcSEcCtD
Fulvestrant—Abdominal pain—Calcitriol—osteoporosis	4.93e-05	0.00102	CcSEcCtD
Fulvestrant—Body temperature increased—Calcitriol—osteoporosis	4.93e-05	0.00102	CcSEcCtD
Fulvestrant—Angioedema—Conjugated Estrogens—osteoporosis	4.91e-05	0.00102	CcSEcCtD
Fulvestrant—Pharyngitis—Estradiol—osteoporosis	4.91e-05	0.00102	CcSEcCtD
Fulvestrant—Hypersensitivity—Estropipate—osteoporosis	4.89e-05	0.00101	CcSEcCtD
Fulvestrant—Nervous system disorder—Pamidronate—osteoporosis	4.89e-05	0.00101	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	4.89e-05	0.00233	CbGpPWpGaD
Fulvestrant—Vomiting—Etidronic acid—osteoporosis	4.88e-05	0.00101	CcSEcCtD
Fulvestrant—Cough—Zoledronate—osteoporosis	4.87e-05	0.00101	CcSEcCtD
Fulvestrant—Oedema peripheral—Estradiol—osteoporosis	4.87e-05	0.00101	CcSEcCtD
Fulvestrant—Connective tissue disorder—Estradiol—osteoporosis	4.86e-05	0.00101	CcSEcCtD
Fulvestrant—Rash—Etidronic acid—osteoporosis	4.84e-05	0.001	CcSEcCtD
Fulvestrant—Dermatitis—Etidronic acid—osteoporosis	4.84e-05	0.001	CcSEcCtD
Fulvestrant—Vertigo—Conjugated Estrogens—osteoporosis	4.83e-05	0.001	CcSEcCtD
Fulvestrant—Hyperhidrosis—Pamidronate—osteoporosis	4.82e-05	0.001	CcSEcCtD
Fulvestrant—Hypersensitivity—Alendronate—osteoporosis	4.82e-05	0.001	CcSEcCtD
Fulvestrant—Headache—Etidronic acid—osteoporosis	4.81e-05	0.000997	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Risedronate—osteoporosis	4.78e-05	0.000992	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—GPD2—osteoporosis	4.77e-05	0.00228	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PGLS—osteoporosis	4.77e-05	0.00228	CbGpPWpGaD
Fulvestrant—Asthenia—Estropipate—osteoporosis	4.77e-05	0.000988	CcSEcCtD
Fulvestrant—Anorexia—Pamidronate—osteoporosis	4.76e-05	0.000986	CcSEcCtD
Fulvestrant—Arthralgia—Zoledronate—osteoporosis	4.75e-05	0.000986	CcSEcCtD
Fulvestrant—Myalgia—Zoledronate—osteoporosis	4.75e-05	0.000986	CcSEcCtD
Fulvestrant—Chest pain—Zoledronate—osteoporosis	4.75e-05	0.000986	CcSEcCtD
Fulvestrant—Insomnia—Risedronate—osteoporosis	4.75e-05	0.000985	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.74e-05	0.00226	CbGpPWpGaD
Fulvestrant—Anxiety—Zoledronate—osteoporosis	4.74e-05	0.000983	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	4.72e-05	0.000979	CcSEcCtD
Fulvestrant—Paraesthesia—Risedronate—osteoporosis	4.71e-05	0.000977	CcSEcCtD
Fulvestrant—Pruritus—Estropipate—osteoporosis	4.7e-05	0.000975	CcSEcCtD
Fulvestrant—Asthenia—Alendronate—osteoporosis	4.69e-05	0.000973	CcSEcCtD
Fulvestrant—Hypersensitivity—Ibandronate—osteoporosis	4.69e-05	0.000973	CcSEcCtD
Fulvestrant—Cough—Conjugated Estrogens—osteoporosis	4.69e-05	0.000973	CcSEcCtD
Fulvestrant—Dyspnoea—Risedronate—osteoporosis	4.68e-05	0.00097	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	4.65e-05	0.000964	CcSEcCtD
Fulvestrant—Fatigue—Ethinyl Estradiol—osteoporosis	4.64e-05	0.000963	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CA2—osteoporosis	4.64e-05	0.00221	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—OXCT1—osteoporosis	4.64e-05	0.00221	CbGpPWpGaD
Fulvestrant—Pruritus—Alendronate—osteoporosis	4.63e-05	0.00096	CcSEcCtD
Fulvestrant—Dyspepsia—Risedronate—osteoporosis	4.62e-05	0.000958	CcSEcCtD
Fulvestrant—Constipation—Ethinyl Estradiol—osteoporosis	4.6e-05	0.000955	CcSEcCtD
Fulvestrant—Hypersensitivity—Calcitriol—osteoporosis	4.59e-05	0.000953	CcSEcCtD
Fulvestrant—Myalgia—Conjugated Estrogens—osteoporosis	4.58e-05	0.000949	CcSEcCtD
Fulvestrant—Chest pain—Conjugated Estrogens—osteoporosis	4.58e-05	0.000949	CcSEcCtD
Fulvestrant—Arthralgia—Conjugated Estrogens—osteoporosis	4.58e-05	0.000949	CcSEcCtD
Fulvestrant—Asthenia—Ibandronate—osteoporosis	4.57e-05	0.000948	CcSEcCtD
Fulvestrant—Anxiety—Conjugated Estrogens—osteoporosis	4.56e-05	0.000946	CcSEcCtD
Fulvestrant—Nausea—Etidronic acid—osteoporosis	4.56e-05	0.000946	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	4.55e-05	0.000943	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Pamidronate—osteoporosis	4.55e-05	0.000943	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	4.54e-05	0.00217	CbGpPWpGaD
Fulvestrant—Diarrhoea—Estropipate—osteoporosis	4.54e-05	0.000942	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Risedronate—osteoporosis	4.53e-05	0.00094	CcSEcCtD
Fulvestrant—Infection—Zoledronate—osteoporosis	4.53e-05	0.000939	CcSEcCtD
Fulvestrant—Fatigue—Risedronate—osteoporosis	4.53e-05	0.000938	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—MGLL—osteoporosis	4.52e-05	0.00216	CbGpPWpGaD
Fulvestrant—Insomnia—Pamidronate—osteoporosis	4.51e-05	0.000936	CcSEcCtD
Fulvestrant—Pruritus—Ibandronate—osteoporosis	4.51e-05	0.000935	CcSEcCtD
Fulvestrant—Constipation—Risedronate—osteoporosis	4.49e-05	0.000931	CcSEcCtD
Fulvestrant—Pain—Risedronate—osteoporosis	4.49e-05	0.000931	CcSEcCtD
Fulvestrant—Angiopathy—Estradiol—osteoporosis	4.49e-05	0.00093	CcSEcCtD
Fulvestrant—Paraesthesia—Pamidronate—osteoporosis	4.48e-05	0.000929	CcSEcCtD
Fulvestrant—Diarrhoea—Alendronate—osteoporosis	4.48e-05	0.000928	CcSEcCtD
Fulvestrant—Asthenia—Calcitriol—osteoporosis	4.47e-05	0.000928	CcSEcCtD
Fulvestrant—Nervous system disorder—Zoledronate—osteoporosis	4.47e-05	0.000927	CcSEcCtD
Fulvestrant—Immune system disorder—Estradiol—osteoporosis	4.47e-05	0.000926	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—ESR2—osteoporosis	4.46e-05	0.00213	CbGpPWpGaD
Fulvestrant—Dyspnoea—Pamidronate—osteoporosis	4.45e-05	0.000923	CcSEcCtD
Fulvestrant—Skin disorder—Zoledronate—osteoporosis	4.43e-05	0.000918	CcSEcCtD
Fulvestrant—Pruritus—Calcitriol—osteoporosis	4.41e-05	0.000915	CcSEcCtD
Fulvestrant—Hyperhidrosis—Zoledronate—osteoporosis	4.41e-05	0.000914	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	4.4e-05	0.000913	CcSEcCtD
Fulvestrant—Diarrhoea—Raloxifene—osteoporosis	4.4e-05	0.000913	CcSEcCtD
Fulvestrant—Dyspepsia—Pamidronate—osteoporosis	4.39e-05	0.000911	CcSEcCtD
Fulvestrant—Dizziness—Estropipate—osteoporosis	4.39e-05	0.000911	CcSEcCtD
Fulvestrant—Infection—Conjugated Estrogens—osteoporosis	4.36e-05	0.000904	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—PNP—osteoporosis	4.36e-05	0.00208	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ATIC—osteoporosis	4.36e-05	0.00208	CbGpPWpGaD
Fulvestrant—Diarrhoea—Ibandronate—osteoporosis	4.36e-05	0.000904	CcSEcCtD
Fulvestrant—Anorexia—Zoledronate—osteoporosis	4.34e-05	0.000901	CcSEcCtD
Fulvestrant—Decreased appetite—Pamidronate—osteoporosis	4.34e-05	0.0009	CcSEcCtD
Fulvestrant—Dizziness—Alendronate—osteoporosis	4.33e-05	0.000897	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—MYC—osteoporosis	4.32e-05	0.00207	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Pamidronate—osteoporosis	4.31e-05	0.000893	CcSEcCtD
Fulvestrant—Nervous system disorder—Conjugated Estrogens—osteoporosis	4.3e-05	0.000893	CcSEcCtD
Fulvestrant—Malnutrition—Estradiol—osteoporosis	4.3e-05	0.000893	CcSEcCtD
Fulvestrant—Fatigue—Pamidronate—osteoporosis	4.3e-05	0.000892	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Risedronate—osteoporosis	4.29e-05	0.00089	CcSEcCtD
Fulvestrant—Urticaria—Ethinyl Estradiol—osteoporosis	4.28e-05	0.000887	CcSEcCtD
Fulvestrant—Pain—Pamidronate—osteoporosis	4.27e-05	0.000885	CcSEcCtD
Fulvestrant—Constipation—Pamidronate—osteoporosis	4.27e-05	0.000885	CcSEcCtD
Fulvestrant—Diarrhoea—Calcitriol—osteoporosis	4.27e-05	0.000885	CcSEcCtD
Fulvestrant—Skin disorder—Conjugated Estrogens—osteoporosis	4.26e-05	0.000884	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.26e-05	0.00203	CbGpPWpGaD
Fulvestrant—Abdominal pain—Ethinyl Estradiol—osteoporosis	4.26e-05	0.000883	CcSEcCtD
Fulvestrant—Body temperature increased—Ethinyl Estradiol—osteoporosis	4.26e-05	0.000883	CcSEcCtD
Fulvestrant—Dizziness—Raloxifene—osteoporosis	4.25e-05	0.000882	CcSEcCtD
Fulvestrant—Hyperhidrosis—Conjugated Estrogens—osteoporosis	4.24e-05	0.00088	CcSEcCtD
Fulvestrant—Vomiting—Estropipate—osteoporosis	4.22e-05	0.000876	CcSEcCtD
Fulvestrant—Dizziness—Ibandronate—osteoporosis	4.21e-05	0.000873	CcSEcCtD
Fulvestrant—Rash—Estropipate—osteoporosis	4.19e-05	0.000868	CcSEcCtD
Fulvestrant—Dermatitis—Estropipate—osteoporosis	4.18e-05	0.000868	CcSEcCtD
Fulvestrant—Anorexia—Conjugated Estrogens—osteoporosis	4.18e-05	0.000868	CcSEcCtD
Fulvestrant—Urticaria—Risedronate—osteoporosis	4.17e-05	0.000865	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—RPL24—osteoporosis	4.17e-05	0.00199	CbGpPWpGaD
Fulvestrant—Back pain—Estradiol—osteoporosis	4.16e-05	0.000863	CcSEcCtD
Fulvestrant—Headache—Estropipate—osteoporosis	4.16e-05	0.000863	CcSEcCtD
Fulvestrant—Vomiting—Alendronate—osteoporosis	4.16e-05	0.000863	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Zoledronate—osteoporosis	4.15e-05	0.000861	CcSEcCtD
Fulvestrant—Body temperature increased—Risedronate—osteoporosis	4.15e-05	0.000861	CcSEcCtD
Fulvestrant—Abdominal pain—Risedronate—osteoporosis	4.15e-05	0.000861	CcSEcCtD
Fulvestrant—Rash—Alendronate—osteoporosis	4.12e-05	0.000855	CcSEcCtD
Fulvestrant—Insomnia—Zoledronate—osteoporosis	4.12e-05	0.000855	CcSEcCtD
Fulvestrant—Dermatitis—Alendronate—osteoporosis	4.12e-05	0.000855	CcSEcCtD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	4.1e-05	0.00196	CbGpPWpGaD
Fulvestrant—Headache—Alendronate—osteoporosis	4.1e-05	0.00085	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—U2AF1—osteoporosis	4.1e-05	0.00196	CbGpPWpGaD
Fulvestrant—Paraesthesia—Zoledronate—osteoporosis	4.09e-05	0.000849	CcSEcCtD
Fulvestrant—Vomiting—Raloxifene—osteoporosis	4.09e-05	0.000848	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Pamidronate—osteoporosis	4.08e-05	0.000846	CcSEcCtD
Fulvestrant—Dyspnoea—Zoledronate—osteoporosis	4.06e-05	0.000843	CcSEcCtD
Fulvestrant—Rash—Raloxifene—osteoporosis	4.06e-05	0.000841	CcSEcCtD
Fulvestrant—Dermatitis—Raloxifene—osteoporosis	4.05e-05	0.00084	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	4.05e-05	0.00193	CbGpPWpGaD
Fulvestrant—Vomiting—Ibandronate—osteoporosis	4.05e-05	0.00084	CcSEcCtD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	4.05e-05	0.00193	CbGpPWpGaD
Fulvestrant—Headache—Raloxifene—osteoporosis	4.03e-05	0.000836	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.03e-05	0.00192	CbGpPWpGaD
Fulvestrant—Rash—Ibandronate—osteoporosis	4.02e-05	0.000833	CcSEcCtD
Fulvestrant—Dermatitis—Ibandronate—osteoporosis	4.01e-05	0.000832	CcSEcCtD
Fulvestrant—Dyspepsia—Zoledronate—osteoporosis	4.01e-05	0.000832	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	4e-05	0.000829	CcSEcCtD
Fulvestrant—Headache—Ibandronate—osteoporosis	3.99e-05	0.000827	CcSEcCtD
Fulvestrant—Insomnia—Conjugated Estrogens—osteoporosis	3.97e-05	0.000823	CcSEcCtD
Fulvestrant—Hypersensitivity—Ethinyl Estradiol—osteoporosis	3.97e-05	0.000823	CcSEcCtD
Fulvestrant—Vomiting—Calcitriol—osteoporosis	3.96e-05	0.000822	CcSEcCtD
Fulvestrant—Decreased appetite—Zoledronate—osteoporosis	3.96e-05	0.000822	CcSEcCtD
Fulvestrant—Nausea—Estropipate—osteoporosis	3.94e-05	0.000818	CcSEcCtD
Fulvestrant—Abdominal pain—Pamidronate—osteoporosis	3.94e-05	0.000818	CcSEcCtD
Fulvestrant—Body temperature increased—Pamidronate—osteoporosis	3.94e-05	0.000818	CcSEcCtD
Fulvestrant—Paraesthesia—Conjugated Estrogens—osteoporosis	3.94e-05	0.000817	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Zoledronate—osteoporosis	3.93e-05	0.000816	CcSEcCtD
Fulvestrant—Angioedema—Estradiol—osteoporosis	3.93e-05	0.000816	CcSEcCtD
Fulvestrant—Rash—Calcitriol—osteoporosis	3.93e-05	0.000815	CcSEcCtD
Fulvestrant—Fatigue—Zoledronate—osteoporosis	3.93e-05	0.000815	CcSEcCtD
Fulvestrant—Dermatitis—Calcitriol—osteoporosis	3.93e-05	0.000815	CcSEcCtD
Fulvestrant—Dyspnoea—Conjugated Estrogens—osteoporosis	3.91e-05	0.000811	CcSEcCtD
Fulvestrant—Headache—Calcitriol—osteoporosis	3.91e-05	0.00081	CcSEcCtD
Fulvestrant—Pain—Zoledronate—osteoporosis	3.9e-05	0.000808	CcSEcCtD
Fulvestrant—Constipation—Zoledronate—osteoporosis	3.9e-05	0.000808	CcSEcCtD
Fulvestrant—NR1H4—Biological oxidations—POMC—osteoporosis	3.9e-05	0.00186	CbGpPWpGaD
Fulvestrant—Nausea—Alendronate—osteoporosis	3.89e-05	0.000806	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—LEP—osteoporosis	3.87e-05	0.00185	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Risedronate—osteoporosis	3.87e-05	0.000802	CcSEcCtD
Fulvestrant—Vertigo—Estradiol—osteoporosis	3.87e-05	0.000802	CcSEcCtD
Fulvestrant—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	3.86e-05	0.00185	CbGpPWpGaD
Fulvestrant—Dyspepsia—Conjugated Estrogens—osteoporosis	3.86e-05	0.000801	CcSEcCtD
Fulvestrant—Asthenia—Ethinyl Estradiol—osteoporosis	3.86e-05	0.000801	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—IDH2—osteoporosis	3.84e-05	0.00183	CbGpPWpGaD
Fulvestrant—Nausea—Raloxifene—osteoporosis	3.82e-05	0.000793	CcSEcCtD
Fulvestrant—Decreased appetite—Conjugated Estrogens—osteoporosis	3.81e-05	0.000791	CcSEcCtD
Fulvestrant—Pruritus—Ethinyl Estradiol—osteoporosis	3.81e-05	0.00079	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	3.79e-05	0.000786	CcSEcCtD
Fulvestrant—Fatigue—Conjugated Estrogens—osteoporosis	3.78e-05	0.000785	CcSEcCtD
Fulvestrant—Nausea—Ibandronate—osteoporosis	3.78e-05	0.000785	CcSEcCtD
Fulvestrant—Asthenia—Risedronate—osteoporosis	3.77e-05	0.000781	CcSEcCtD
Fulvestrant—Cough—Estradiol—osteoporosis	3.76e-05	0.000779	CcSEcCtD
Fulvestrant—Constipation—Conjugated Estrogens—osteoporosis	3.75e-05	0.000778	CcSEcCtD
Fulvestrant—Pain—Conjugated Estrogens—osteoporosis	3.75e-05	0.000778	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Zoledronate—osteoporosis	3.73e-05	0.000773	CcSEcCtD
Fulvestrant—Pruritus—Risedronate—osteoporosis	3.71e-05	0.00077	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—OXCT1—osteoporosis	3.71e-05	0.00177	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CA2—osteoporosis	3.71e-05	0.00177	CbGpPWpGaD
Fulvestrant—Nausea—Calcitriol—osteoporosis	3.7e-05	0.000768	CcSEcCtD
Fulvestrant—Diarrhoea—Ethinyl Estradiol—osteoporosis	3.68e-05	0.000764	CcSEcCtD
Fulvestrant—Hypersensitivity—Pamidronate—osteoporosis	3.68e-05	0.000762	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—FDPS—osteoporosis	3.67e-05	0.00175	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PKM—osteoporosis	3.67e-05	0.00175	CbGpPWpGaD
Fulvestrant—Arthralgia—Estradiol—osteoporosis	3.66e-05	0.00076	CcSEcCtD
Fulvestrant—Myalgia—Estradiol—osteoporosis	3.66e-05	0.00076	CcSEcCtD
Fulvestrant—Chest pain—Estradiol—osteoporosis	3.66e-05	0.00076	CcSEcCtD
Fulvestrant—Anxiety—Estradiol—osteoporosis	3.65e-05	0.000757	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	3.64e-05	0.000755	CcSEcCtD
Fulvestrant—Urticaria—Zoledronate—osteoporosis	3.62e-05	0.000751	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—MGLL—osteoporosis	3.61e-05	0.00172	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP27A1—osteoporosis	3.61e-05	0.00172	CbGpPWpGaD
Fulvestrant—Body temperature increased—Zoledronate—osteoporosis	3.6e-05	0.000747	CcSEcCtD
Fulvestrant—Abdominal pain—Zoledronate—osteoporosis	3.6e-05	0.000747	CcSEcCtD
Fulvestrant—Diarrhoea—Risedronate—osteoporosis	3.59e-05	0.000745	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	3.59e-05	0.000744	CcSEcCtD
Fulvestrant—Asthenia—Pamidronate—osteoporosis	3.58e-05	0.000742	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL6R—osteoporosis	3.58e-05	0.00171	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—U2AF1—osteoporosis	3.57e-05	0.0017	CbGpPWpGaD
Fulvestrant—Dizziness—Ethinyl Estradiol—osteoporosis	3.56e-05	0.000738	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—VDR—osteoporosis	3.54e-05	0.00169	CbGpPWpGaD
Fulvestrant—Pruritus—Pamidronate—osteoporosis	3.53e-05	0.000732	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—ACP5—osteoporosis	3.51e-05	0.00168	CbGpPWpGaD
Fulvestrant—Infection—Estradiol—osteoporosis	3.49e-05	0.000724	CcSEcCtD
Fulvestrant—Urticaria—Conjugated Estrogens—osteoporosis	3.49e-05	0.000723	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—PGLS—osteoporosis	3.48e-05	0.00166	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GPD2—osteoporosis	3.48e-05	0.00166	CbGpPWpGaD
Fulvestrant—Dizziness—Risedronate—osteoporosis	3.47e-05	0.00072	CcSEcCtD
Fulvestrant—Body temperature increased—Conjugated Estrogens—osteoporosis	3.47e-05	0.000719	CcSEcCtD
Fulvestrant—Abdominal pain—Conjugated Estrogens—osteoporosis	3.47e-05	0.000719	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.47e-05	0.00166	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.47e-05	0.00166	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—IRS1—osteoporosis	3.45e-05	0.00165	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Estradiol—osteoporosis	3.44e-05	0.000714	CcSEcCtD
Fulvestrant—Vomiting—Ethinyl Estradiol—osteoporosis	3.42e-05	0.00071	CcSEcCtD
Fulvestrant—Diarrhoea—Pamidronate—osteoporosis	3.41e-05	0.000708	CcSEcCtD
Fulvestrant—Skin disorder—Estradiol—osteoporosis	3.41e-05	0.000708	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.41e-05	0.00163	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Estradiol—osteoporosis	3.4e-05	0.000704	CcSEcCtD
Fulvestrant—Rash—Ethinyl Estradiol—osteoporosis	3.39e-05	0.000704	CcSEcCtD
Fulvestrant—Dermatitis—Ethinyl Estradiol—osteoporosis	3.39e-05	0.000703	CcSEcCtD
Fulvestrant—Headache—Ethinyl Estradiol—osteoporosis	3.37e-05	0.000699	CcSEcCtD
Fulvestrant—Hypersensitivity—Zoledronate—osteoporosis	3.36e-05	0.000696	CcSEcCtD
Fulvestrant—Vomiting—Risedronate—osteoporosis	3.34e-05	0.000692	CcSEcCtD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	3.32e-05	0.00159	CbGpPWpGaD
Fulvestrant—Rash—Risedronate—osteoporosis	3.31e-05	0.000686	CcSEcCtD
Fulvestrant—Dermatitis—Risedronate—osteoporosis	3.31e-05	0.000686	CcSEcCtD
Fulvestrant—Dizziness—Pamidronate—osteoporosis	3.3e-05	0.000684	CcSEcCtD
Fulvestrant—Headache—Risedronate—osteoporosis	3.29e-05	0.000682	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—KL—osteoporosis	3.28e-05	0.00156	CbGpPWpGaD
Fulvestrant—Asthenia—Zoledronate—osteoporosis	3.27e-05	0.000678	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—TPI1—osteoporosis	3.27e-05	0.00156	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—ESR2—osteoporosis	3.26e-05	0.00156	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Conjugated Estrogens—osteoporosis	3.23e-05	0.000671	CcSEcCtD
Fulvestrant—Pruritus—Zoledronate—osteoporosis	3.22e-05	0.000669	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Estradiol—osteoporosis	3.2e-05	0.000664	CcSEcCtD
Fulvestrant—Nausea—Ethinyl Estradiol—osteoporosis	3.2e-05	0.000663	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—ATIC—osteoporosis	3.19e-05	0.00152	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PNP—osteoporosis	3.19e-05	0.00152	CbGpPWpGaD
Fulvestrant—Insomnia—Estradiol—osteoporosis	3.18e-05	0.000659	CcSEcCtD
Fulvestrant—Vomiting—Pamidronate—osteoporosis	3.17e-05	0.000658	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	3.16e-05	0.00151	CbGpPWpGaD
Fulvestrant—Paraesthesia—Estradiol—osteoporosis	3.15e-05	0.000654	CcSEcCtD
Fulvestrant—Asthenia—Conjugated Estrogens—osteoporosis	3.15e-05	0.000653	CcSEcCtD
Fulvestrant—Rash—Pamidronate—osteoporosis	3.15e-05	0.000652	CcSEcCtD
Fulvestrant—Dermatitis—Pamidronate—osteoporosis	3.14e-05	0.000652	CcSEcCtD
Fulvestrant—Dyspnoea—Estradiol—osteoporosis	3.13e-05	0.000649	CcSEcCtD
Fulvestrant—Headache—Pamidronate—osteoporosis	3.13e-05	0.000648	CcSEcCtD
Fulvestrant—Diarrhoea—Zoledronate—osteoporosis	3.12e-05	0.000647	CcSEcCtD
Fulvestrant—Nausea—Risedronate—osteoporosis	3.12e-05	0.000647	CcSEcCtD
Fulvestrant—Pruritus—Conjugated Estrogens—osteoporosis	3.1e-05	0.000644	CcSEcCtD
Fulvestrant—Dyspepsia—Estradiol—osteoporosis	3.09e-05	0.000641	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—P4HB—osteoporosis	3.07e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—IDH2—osteoporosis	3.07e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—MYC—osteoporosis	3.05e-05	0.00146	CbGpPWpGaD
Fulvestrant—Decreased appetite—Estradiol—osteoporosis	3.05e-05	0.000633	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—RPL24—osteoporosis	3.04e-05	0.00145	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Estradiol—osteoporosis	3.03e-05	0.000629	CcSEcCtD
Fulvestrant—Fatigue—Estradiol—osteoporosis	3.03e-05	0.000628	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GAPDH—osteoporosis	3.01e-05	0.00144	CbGpPWpGaD
Fulvestrant—Dizziness—Zoledronate—osteoporosis	3.01e-05	0.000625	CcSEcCtD
Fulvestrant—Pain—Estradiol—osteoporosis	3e-05	0.000623	CcSEcCtD
Fulvestrant—Constipation—Estradiol—osteoporosis	3e-05	0.000623	CcSEcCtD
Fulvestrant—Diarrhoea—Conjugated Estrogens—osteoporosis	3e-05	0.000623	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3e-05	0.00143	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—MYC—osteoporosis	3e-05	0.00143	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	2.97e-05	0.00142	CbGpPWpGaD
Fulvestrant—Nausea—Pamidronate—osteoporosis	2.96e-05	0.000615	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—RAP1A—osteoporosis	2.94e-05	0.0014	CbGpPWpGaD
Fulvestrant—Dizziness—Conjugated Estrogens—osteoporosis	2.9e-05	0.000602	CcSEcCtD
Fulvestrant—Vomiting—Zoledronate—osteoporosis	2.9e-05	0.000601	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CYP27A1—osteoporosis	2.89e-05	0.00138	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	2.88e-05	0.00138	CbGpPWpGaD
Fulvestrant—Rash—Zoledronate—osteoporosis	2.87e-05	0.000596	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Estradiol—osteoporosis	2.87e-05	0.000596	CcSEcCtD
Fulvestrant—Dermatitis—Zoledronate—osteoporosis	2.87e-05	0.000595	CcSEcCtD
Fulvestrant—Headache—Zoledronate—osteoporosis	2.86e-05	0.000592	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—MYC—osteoporosis	2.84e-05	0.00136	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ACP5—osteoporosis	2.81e-05	0.00134	CbGpPWpGaD
Fulvestrant—Vomiting—Conjugated Estrogens—osteoporosis	2.79e-05	0.000579	CcSEcCtD
Fulvestrant—Urticaria—Estradiol—osteoporosis	2.79e-05	0.000579	CcSEcCtD
Fulvestrant—Body temperature increased—Estradiol—osteoporosis	2.78e-05	0.000576	CcSEcCtD
Fulvestrant—Abdominal pain—Estradiol—osteoporosis	2.78e-05	0.000576	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.77e-05	0.00132	CbGpPWpGaD
Fulvestrant—Rash—Conjugated Estrogens—osteoporosis	2.77e-05	0.000574	CcSEcCtD
Fulvestrant—Dermatitis—Conjugated Estrogens—osteoporosis	2.76e-05	0.000573	CcSEcCtD
Fulvestrant—Headache—Conjugated Estrogens—osteoporosis	2.75e-05	0.00057	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL1B—osteoporosis	2.72e-05	0.0013	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CA2—osteoporosis	2.71e-05	0.00129	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—OXCT1—osteoporosis	2.71e-05	0.00129	CbGpPWpGaD
Fulvestrant—Nausea—Zoledronate—osteoporosis	2.71e-05	0.000561	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—ESR1—osteoporosis	2.71e-05	0.00129	CbGpPWpGaD
Fulvestrant—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	2.66e-05	0.00127	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—RPL24—osteoporosis	2.65e-05	0.00127	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—TNF—osteoporosis	2.65e-05	0.00126	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MGLL—osteoporosis	2.64e-05	0.00126	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—TPI1—osteoporosis	2.61e-05	0.00125	CbGpPWpGaD
Fulvestrant—Nausea—Conjugated Estrogens—osteoporosis	2.61e-05	0.000541	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—VDR—osteoporosis	2.59e-05	0.00124	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Estradiol—osteoporosis	2.59e-05	0.000537	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.56e-05	0.00122	CbGpPWpGaD
Fulvestrant—Asthenia—Estradiol—osteoporosis	2.52e-05	0.000523	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.49e-05	0.00119	CbGpPWpGaD
Fulvestrant—Pruritus—Estradiol—osteoporosis	2.48e-05	0.000515	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—IL1B—osteoporosis	2.47e-05	0.00118	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—P4HB—osteoporosis	2.46e-05	0.00117	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GAPDH—osteoporosis	2.41e-05	0.00115	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PSMA5—osteoporosis	2.4e-05	0.00115	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PSMA2—osteoporosis	2.4e-05	0.00115	CbGpPWpGaD
Fulvestrant—Diarrhoea—Estradiol—osteoporosis	2.4e-05	0.000498	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—ENO1—osteoporosis	2.37e-05	0.00113	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—RAP1A—osteoporosis	2.35e-05	0.00112	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PSMA2—osteoporosis	2.34e-05	0.00112	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PSMA5—osteoporosis	2.34e-05	0.00112	CbGpPWpGaD
Fulvestrant—Dizziness—Estradiol—osteoporosis	2.32e-05	0.000482	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—VDR—osteoporosis	2.25e-05	0.00108	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IRS2—osteoporosis	2.25e-05	0.00107	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—IDH2—osteoporosis	2.24e-05	0.00107	CbGpPWpGaD
Fulvestrant—Vomiting—Estradiol—osteoporosis	2.23e-05	0.000463	CcSEcCtD
Fulvestrant—Rash—Estradiol—osteoporosis	2.21e-05	0.000459	CcSEcCtD
Fulvestrant—Dermatitis—Estradiol—osteoporosis	2.21e-05	0.000459	CcSEcCtD
Fulvestrant—Headache—Estradiol—osteoporosis	2.2e-05	0.000456	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—osteoporosis	2.18e-05	0.00104	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	2.15e-05	0.00103	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR2—osteoporosis	2.15e-05	0.00103	CbGpPWpGaD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	2.13e-05	0.00102	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP27A1—osteoporosis	2.11e-05	0.00101	CbGpPWpGaD
Fulvestrant—Nausea—Estradiol—osteoporosis	2.09e-05	0.000433	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—osteoporosis	2.08e-05	0.000992	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—TGFB1—osteoporosis	2.07e-05	0.00099	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ACP5—osteoporosis	2.05e-05	0.00098	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.05e-05	0.000977	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—osteoporosis	2.03e-05	0.000969	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.03e-05	0.000968	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TGFB1—osteoporosis	2.02e-05	0.000967	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—ESR1—osteoporosis	1.98e-05	0.000944	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—TNF—osteoporosis	1.98e-05	0.000943	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—IRS1—osteoporosis	1.97e-05	0.000941	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IRS1—osteoporosis	1.96e-05	0.000936	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.93e-05	0.000923	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—TPI1—osteoporosis	1.91e-05	0.000911	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP19A1—osteoporosis	1.9e-05	0.000906	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ENO1—osteoporosis	1.9e-05	0.000906	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PSMA5—osteoporosis	1.87e-05	0.000893	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PSMA2—osteoporosis	1.87e-05	0.000893	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6R—osteoporosis	1.84e-05	0.00088	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	1.81e-05	0.000862	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.8e-05	0.000861	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—U2AF1—osteoporosis	1.8e-05	0.000859	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.8e-05	0.000859	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—P4HB—osteoporosis	1.79e-05	0.000857	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	1.77e-05	0.000843	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GAPDH—osteoporosis	1.76e-05	0.000841	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PSMA2—osteoporosis	1.76e-05	0.000839	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PSMA5—osteoporosis	1.76e-05	0.000839	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—IL6—osteoporosis	1.75e-05	0.000835	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	1.75e-05	0.000834	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	1.74e-05	0.000832	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—ESR1—osteoporosis	1.72e-05	0.000822	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—RAP1A—osteoporosis	1.72e-05	0.000819	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—VDR—osteoporosis	1.71e-05	0.000814	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.68e-05	0.000802	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL6—osteoporosis	1.59e-05	0.000761	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR2—osteoporosis	1.57e-05	0.00075	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ADCY5—osteoporosis	1.55e-05	0.00074	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GPX1—osteoporosis	1.54e-05	0.000738	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PSMA2—osteoporosis	1.53e-05	0.000731	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PSMA5—osteoporosis	1.53e-05	0.000731	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL6—osteoporosis	1.53e-05	0.000729	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP19A1—osteoporosis	1.52e-05	0.000724	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	1.51e-05	0.000723	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.5e-05	0.000714	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—ESR2—osteoporosis	1.43e-05	0.000684	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—MTHFR—osteoporosis	1.43e-05	0.000681	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—osteoporosis	1.41e-05	0.000672	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ENO1—osteoporosis	1.39e-05	0.000662	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PSMA5—osteoporosis	1.37e-05	0.000652	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PSMA2—osteoporosis	1.37e-05	0.000652	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SOST—osteoporosis	1.35e-05	0.000644	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—RPL24—osteoporosis	1.34e-05	0.000638	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR1—osteoporosis	1.3e-05	0.000622	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	1.29e-05	0.000618	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—VDR—osteoporosis	1.25e-05	0.000595	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ADCY5—osteoporosis	1.24e-05	0.000592	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GPX1—osteoporosis	1.24e-05	0.00059	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CALCR—osteoporosis	1.22e-05	0.000583	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTH1R—osteoporosis	1.22e-05	0.000583	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—POMC—osteoporosis	1.14e-05	0.000545	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—MTHFR—osteoporosis	1.14e-05	0.000544	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—VDR—osteoporosis	1.14e-05	0.000543	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP19A1—osteoporosis	1.11e-05	0.000529	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—osteoporosis	1.1e-05	0.000524	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—VDR—osteoporosis	1.09e-05	0.000518	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.05e-05	0.000501	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—osteoporosis	1.03e-05	0.000491	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MGLL—osteoporosis	9.69e-06	0.000463	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR1—osteoporosis	9.52e-06	0.000455	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LRP5—osteoporosis	9.46e-06	0.000452	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	9.28e-06	0.000443	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	9.15e-06	0.000437	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—POMC—osteoporosis	9.12e-06	0.000435	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	9.09e-06	0.000434	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	9.07e-06	0.000433	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ADCY5—osteoporosis	9.06e-06	0.000432	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LRP6—osteoporosis	9.05e-06	0.000432	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GPX1—osteoporosis	9.03e-06	0.000431	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—osteoporosis	8.96e-06	0.000428	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	8.47e-06	0.000404	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—osteoporosis	8.33e-06	0.000398	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ESR1—osteoporosis	8.29e-06	0.000396	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6—osteoporosis	8.21e-06	0.000392	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PSMA2—osteoporosis	7.72e-06	0.000368	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PSMA5—osteoporosis	7.72e-06	0.000368	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TLN1—osteoporosis	7.64e-06	0.000365	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—ESR2—osteoporosis	6.89e-06	0.000329	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—osteoporosis	6.78e-06	0.000324	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—POMC—osteoporosis	6.66e-06	0.000318	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—P4HB—osteoporosis	6.59e-06	0.000315	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTH—osteoporosis	6.41e-06	0.000306	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RAP1A—osteoporosis	6.3e-06	0.000301	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CNR2—osteoporosis	6.25e-06	0.000298	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NFATC1—osteoporosis	6.14e-06	0.000293	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—DKK1—osteoporosis	6.1e-06	0.000291	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—WNT1—osteoporosis	5.87e-06	0.00028	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGA—osteoporosis	5.71e-06	0.000273	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—POMC—osteoporosis	5.58e-06	0.000266	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—VDR—osteoporosis	5.47e-06	0.000261	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTHLH—osteoporosis	5.31e-06	0.000254	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BMP2—osteoporosis	5.31e-06	0.000254	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PKM—osteoporosis	5.26e-06	0.000251	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—FDPS—osteoporosis	5.26e-06	0.000251	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGB—osteoporosis	5.2e-06	0.000248	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PSMA5—osteoporosis	5.02e-06	0.00024	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PSMA2—osteoporosis	5.02e-06	0.00024	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PGLS—osteoporosis	4.99e-06	0.000238	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GPD2—osteoporosis	4.99e-06	0.000238	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—osteoporosis	4.95e-06	0.000236	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CALCA—osteoporosis	4.68e-06	0.000223	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PNP—osteoporosis	4.56e-06	0.000218	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ATIC—osteoporosis	4.56e-06	0.000218	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—osteoporosis	4.52e-06	0.000216	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—osteoporosis	4.31e-06	0.000206	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KL—osteoporosis	4.25e-06	0.000203	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—OXCT1—osteoporosis	3.88e-06	0.000185	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA2—osteoporosis	3.88e-06	0.000185	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MGLL—osteoporosis	3.78e-06	0.00018	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ADCY5—osteoporosis	3.33e-06	0.000159	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SPP1—osteoporosis	3.22e-06	0.000154	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—IDH2—osteoporosis	3.21e-06	0.000153	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.02e-06	0.000144	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ACP5—osteoporosis	2.94e-06	0.00014	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IRS2—osteoporosis	2.91e-06	0.000139	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LEP—osteoporosis	2.85e-06	0.000136	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TPI1—osteoporosis	2.73e-06	0.00013	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—P4HB—osteoporosis	2.57e-06	0.000123	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IRS1—osteoporosis	2.54e-06	0.000121	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GAPDH—osteoporosis	2.52e-06	0.00012	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—RAP1A—osteoporosis	2.46e-06	0.000117	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—POMC—osteoporosis	2.45e-06	0.000117	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6R—osteoporosis	2.39e-06	0.000114	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IGF1—osteoporosis	2.35e-06	0.000112	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—osteoporosis	2.17e-06	0.000104	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ENO1—osteoporosis	1.98e-06	9.48e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PSMA2—osteoporosis	1.96e-06	9.34e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PSMA5—osteoporosis	1.96e-06	9.34e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.59e-06	7.58e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—osteoporosis	1.41e-06	6.75e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFB1—osteoporosis	1.41e-06	6.74e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ADCY5—osteoporosis	1.3e-06	6.19e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GPX1—osteoporosis	1.29e-06	6.17e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—osteoporosis	1.19e-06	5.69e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6—osteoporosis	1.06e-06	5.08e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—POMC—osteoporosis	9.54e-07	4.55e-05	CbGpPWpGaD
